Literature DB >> 30948486

Response assessment in acute myeloid leukemia by flow cytometry supersedes cytomorphology at time of aplasia, amends cases without molecular residual disease marker and serves as an independent prognostic marker at time of aplasia and post-induction.

Thomas Köhnke1,2, Veit Bücklein1,2, Sandra Rechkemmer1, Stephanie Schneider1,3, Maja Rothenberg-Thurley1,4,5, Klaus H Metzeler1,4,5, Maria-Cristina Sauerland6, Wolfgang Hiddemann1,4,5, Karsten Spiekermann1,4,5, Marion Subklewe7,2,4,5.   

Abstract

Entities:  

Year:  2019        PMID: 30948486      PMCID: PMC6821611          DOI: 10.3324/haematol.2018.215236

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  10 in total

1.  Flow cytometric demonstration of decrease in bone marrow leukemic blasts after 'Day 14' without further therapy in acute myeloid leukemia.

Authors:  Xueyan Chen; Megan Othus; Brent L Wood; Roland B Walter; Mary-Elizabeth M Percival; Pamela S Becker; Paul C Hendrie; Frederick R Appelbaum; Elihu H Estey
Journal:  Leuk Lymphoma       Date:  2017-03-28

Review 2.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Authors:  Hartmut Döhner; Elihu Estey; David Grimwade; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Hervé Dombret; Benjamin L Ebert; Pierre Fenaux; Richard A Larson; Ross L Levine; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel Sanz; Jorge Sierra; Martin S Tallman; Hwei-Fang Tien; Andrew H Wei; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2016-11-28       Impact factor: 22.113

3.  Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia.

Authors:  Hiroto Inaba; Elaine Coustan-Smith; Xueyuan Cao; Stanley B Pounds; Sheila A Shurtleff; Kathleen Y Wang; Susana C Raimondi; Mihaela Onciu; Jeffrey Jacobsen; Raul C Ribeiro; Gary V Dahl; W Paul Bowman; Jeffrey W Taub; Barbara Degar; Wing Leung; James R Downing; Ching-Hon Pui; Jeffrey E Rubnitz; Dario Campana
Journal:  J Clin Oncol       Date:  2012-09-10       Impact factor: 44.544

4.  High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.

Authors:  Monique Terwijn; Wim L J van Putten; Angèle Kelder; Vincent H J van der Velden; Rik A Brooimans; Thomas Pabst; Johan Maertens; Nancy Boeckx; Georgine E de Greef; Peter J M Valk; Frank W M B Preijers; Peter C Huijgens; Angelika M Dräger; Urs Schanz; Mojca Jongen-Lavrecic; Bart J Biemond; Jakob R Passweg; Michel van Gelder; Pierre Wijermans; Carlos Graux; Mario Bargetzi; Marie-Cecile Legdeur; Jurgen Kuball; Okke de Weerdt; Yves Chalandon; Urs Hess; Leo F Verdonck; Jan W Gratama; Yvonne J M Oussoren; Willemijn J Scholten; Jennita Slomp; Alexander N Snel; Marie-Christiane Vekemans; Bob Löwenberg; Gert J Ossenkoppele; Gerrit J Schuurhuis
Journal:  J Clin Oncol       Date:  2013-09-23       Impact factor: 44.544

5.  Molecular Minimal Residual Disease in Acute Myeloid Leukemia.

Authors:  Mojca Jongen-Lavrencic; Tim Grob; Diana Hanekamp; François G Kavelaars; Adil Al Hinai; Annelieke Zeilemaker; Claudia A J Erpelinck-Verschueren; Patrycja L Gradowska; Rosa Meijer; Jacqueline Cloos; Bart J Biemond; Carlos Graux; Marinus van Marwijk Kooy; Markus G Manz; Thomas Pabst; Jakob R Passweg; Violaine Havelange; Gert J Ossenkoppele; Mathijs A Sanders; Gerrit J Schuurhuis; Bob Löwenberg; Peter J M Valk
Journal:  N Engl J Med       Date:  2018-03-29       Impact factor: 91.245

6.  Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse.

Authors:  T Köhnke; D Sauter; K Ringel; E Hoster; R P Laubender; M Hubmann; S K Bohlander; P M Kakadia; S Schneider; A Dufour; M-C Sauerland; W E Berdel; T Büchner; B Wörmann; J Braess; W Hiddemann; K Spiekermann; M Subklewe
Journal:  Leukemia       Date:  2014-06-10       Impact factor: 11.528

7.  Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.

Authors:  Wolfgang Kern; Torsten Haferlach; Claudia Schoch; Helmut Loffler; Winfried Gassmann; Achim Heinecke; Maria Christina Sauerland; Wolfgang Berdel; Thomas Buchner; Wolfgang Hiddemann
Journal:  Blood       Date:  2002-06-28       Impact factor: 22.113

8.  Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia.

Authors:  R B Walter; M Othus; E M Paietta; J Racevskis; H F Fernandez; J-W Lee; Z Sun; M S Tallman; J Patel; M Gönen; O Abdel-Wahab; R L Levine; E H Estey
Journal:  Leukemia       Date:  2015-03-16       Impact factor: 11.528

9.  Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia.

Authors:  Sylvie D Freeman; Paul Virgo; Steve Couzens; David Grimwade; Nigel Russell; Robert K Hills; Alan K Burnett
Journal:  J Clin Oncol       Date:  2013-09-23       Impact factor: 44.544

10.  Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study.

Authors:  Jan Braess; Susanne Amler; Karl-Anton Kreuzer; Karsten Spiekermann; Hans Walter Lindemann; Eva Lengfelder; Ullrich Graeven; Peter Staib; Wolf-Dieter Ludwig; Harald Biersack; Yon-Dschun Ko; Michael J Uppenkamp; Maike De Wit; Stefan Korsten; Rudolf Peceny; Tobias Gaska; Xaver Schiel; Dirk M Behringer; Michael G Kiehl; Bettina Zinngrebe; Gerald Meckenstock; Eva Roemer; Dirk Medgenberg; Ernst Spaeth-Schwalbe; Gero Massenkeil; Heidrun Hindahl; Rainer Schwerdtfeger; Guido Trenn; Cristina Sauerland; Raphael Koch; Martin Lablans; Andreas Faldum; Dennis Görlich; Stefan K Bohlander; Stephanie Schneider; Annika Dufour; Christian Buske; Michael Fiegl; Marion Subklewe; Birgit Braess; Michael Unterhalt; Anja Baumgartner; Bernhard Wörmann; Dietrich Beelen; Wolfgang Hiddemann
Journal:  Leukemia       Date:  2018-10-01       Impact factor: 11.528

  10 in total
  1 in total

1.  Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia.

Authors:  Uta Oelschlägel; Malte von Bonin; Maximilian A Röhnert; Michael Kramer; Jonas Schadt; Philipp Ensel; Christian Thiede; Stefan W Krause; Veit Bücklein; Jörg Hoffmann; Sonia Jaramillo; Richard F Schlenk; Christoph Röllig; Martin Bornhäuser; Nicholas McCarthy; Sylvie Freeman
Journal:  Leukemia       Date:  2022-07-18       Impact factor: 12.883

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.